Ειδήσεις: PERSPECTIVE THERAPEUTICS | PXAI

Version	Description	Date
8.42	[ADDED SOURCE REGISTRY LIST VIEW]	04/03/2026 16:19
8.41	[LOCALIZED INDEX.PHP MENU AND MODALS TO US ENGLISH]	04/03/2026 16:11
8.40	[TRANSLATED FRONTEND TO US ENGLISH]	04/03/2026 16:10
8.41	[RESTORED DETAILED SOURCES VIEW (ARTICLES + EVENTS) IN US ENGLISH]	04/03/2026 15:50
8.41	[RESTORED DETAILED SOURCES VIEW (ARTICLES + EVENTS) IN US ENGLISH]	04/03/2026 15:46
8.40	[REVERTED TO STANDARD TABLE LAYOUT (US ENGLISH)]	04/03/2026 15:40
8.39	[FIXED DB CONNECTION SCOPE IN SOURCES LOGIC]	04/03/2026 15:38
8.38	[TRANSLATED SOURCES VIEW TO US ENGLISH]	04/03/2026 15:01
8.37	[FULL FRONTEND TRANSLATION (MENU, FEED, COMMENTS, TTS) TO US ENGLISH.]	04/03/2026 14:58
8.67	[MANUAL OVERRIDE OF GREEK MENU ITEMS]	04/03/2026 13:36
8.66	[NGINX OPTIMIZED MENU FIX]	04/03/2026 13:33
8.65	[FIXED GREEK MENU ITEMS]	04/03/2026 13:32
8.60	[MENU & UI LOCALIZATION TO US ENGLISH]	04/03/2026 13:30
8.50	[FULL TRANSLATION TO US ENGLISH]	04/03/2026 13:27
9.75	[INJECTED EVENT FUSION_SUMMARY INTO FEED LOOPS TO DISPLAY AI TAGS CORRECTLY]	26/02/2026 14:44

24/03 19:45 defenseworld.net

Perspective Therapeutics (NYSEAMERICAN:CATX) Given New $13.00 Price Target at HC Wainwright

Perspective Therapeutics CATX price target HC Wainwright BTIG Truist

19/03 08:58 defenseworld.net

Perspective Therapeutics (NYSEAMERICAN:CATX) Given New $8.00 Price Target at UBS Group

Perspective Therapeutics CATX price target UBS Group Wedbush RBC

19/03 08:58 defenseworld.net

Perspective Therapeutics (NYSEAMERICAN:CATX) Receives Outperform Rating from Wedbush

Perspective Therapeutics CATX analyst ratings Wedbush Piper Sandler Truist

19/03 08:58 defenseworld.net

Perspective Therapeutics (NYSEAMERICAN:CATX) Price Target Raised to $13.00 at B. Riley Financial

Perspective Therapeutics price target B Riley Financial buy rating stock analysis

19/03 08:58 defenseworld.net

Perspective Therapeutics (NYSEAMERICAN:CATX) Price Target Raised to $13.00 at B. Riley Financial

Perspective Therapeutics price target B Riley Financial buy rating stock analysis

Loading...